RTRebecca Thursfield

Rebecca Thursfield

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Rebecca Thursfield has a total of 122 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Development of a lifelong core outcome set for oesophageal atresia ± tracheoesophageal fistula: the OCELOT study

    by Rebecca Thursfield, Sarah Gorst, Nadine Teunisson, Nick Lansdale, Julia Faulkner, Usha Krishnan, Tom Kovesi, Graham Slater, Paul Cullis, Lucy Bray, et al.

    Background Despite anatomical correction, people born with oesophageal atresia±tracheoesophageal fistula (OA-TOF) experience lifelong morbidity. Core outcome sets (COSs) are recognised as a means of improving research quality and, as a consequence, improving patient outcomes; one was not available for this population. Objective The scope of the study was to develop a COS for people born with OA-TOF that would be applicable regardless of age or geographic location. Study design Patient input was paramount to this study. For long-list generation, in addition to the systematic review (SR), patients and representatives were invited to participate in focus groups, interviews or complete activity packs to ascertain outcomes that matter most to them. International consensus was then sought using a two-step Delphi survey followed by an online consensus meeting. Results Eight outcomes were identified through patient events that had not been picked up from SR. 175 people completed the Delphi survey from 26 countries and health care professionals from 13 different disciplines. 24 outcomes met predefined criteria for inclusion and following discussion and voting in the consensus meeting, and 14/24 outcomes were agreed for inclusion in the COS. Conclusion 14 outcomes have been agreed on to form the COS. 12 of these outcomes are relevant to people of all ages, 1 to paediatric population and 1 to adult cohorts. The COS is, therefore, truly applicable lifelong, which was the scope of the project. This COS will help reduce research heterogeneity, enabling better quality research outcomes and more comparable data.


  • Open Access

    Surgery versus conservative management for severe pectus excavatum (RESTORE): protocol for a multicentre, randomised, controlled superiority trial

    by Rebecca Maier, Joel Dunning, James Wason, Thomas Chadwick, Andrew Bryant, Cristina Fernandez-Garcia, Luke Vale, Gerard R Danjoux, Gillian Wallace, Alistair Levett-Renton, et al.

    Introduction: Severe pectus excavatum (PE) may impair cardiopulmonary and physical function. The effectiveness of surgical treatment to correct PE and restore physical function is widely debated due to a lack of high-quality comparative evidence. The RESTORE trial aims to determine the clinical and cost-effectiveness of corrective surgery for severe PE compared with conservative management for the first time in a randomised controlled trial (RCT). Methods and analysis: RESTORE is a pragmatic, multicentre, RCT with an embedded observational cohort. 200 participants aged ≥12 years with severe PE will be recruited at around 12 National Health Service cardiothoracic surgical centres in England. Participants will be randomised 1:1 to receive either surgery within 3 months of randomisation (intervention arm) or no surgery until after the primary outcome measurement at 1 year (comparator arm). The primary outcome is change in physical functioning from baseline to 1 year as measured by the Short Form Health Survey (SF-36v2) physical function score. The primary economic outcome is cost-effectiveness. The key secondary outcome is change in % predicted VO 2peak at 1 year measured by cardiopulmonary exercise test (CPET). Outcomes will be assessed at 1 year post-randomisation in the comparator arm and 1 year post-surgery in the intervention arm. The primary analyses will be undertaken on an intention-to-treat population using a linear mixed-effects model, adjusted for stratification variables via a binary covariate. Other secondary outcomes will include change from baseline of cardiopulmonary function (CPET and spirometry), health-related quality of life using the EuroQol 5 Dimension 5 Level (EQ-5D-5L) and SF-36v2 questionnaires, Hospital Anxiety and Depression Scale and disease specific symptoms (Phoenix Comprehensive Assessment for Pectus Excavatum Symptoms and Pectus Excavatum Evaluation Questionnaire). Adverse events, complications from surgery and operative technical success (Haller and Compression Indices from preoperative and postoperative CT scans) will also be assessed. Health economic analysis will estimate the incremental cost per quality adjusted life year at 1 year. Ethics and dissemination: The trial was approved by East of Scotland Research and Ethics Service (24/ES/0034). Participants who are ≥16 years of age will be required to provide written informed consent. For participants <16 years of age who are not judged to be Gillick competent, written assent and written informed consent from a parent/guardian will be required. Results will be submitted for publication in peer-reviewed journals and shared with participants, clinicians and commissioners. Trial registration number: ISRCTN11359779 .

  • Open Access

    Developing a core outcome set for the health outcomes for children and adults with congenital oesophageal atresia and/or tracheo-oesophageal fistula: OCELOT task group study protocol

    by Jonathan Ducey, Nick Lansdale, Sarah Gorst, Lucy Bray, Nadine Teunissen, Paul Cullis, Julia Faulkner, Victoria Gray, Lucia Gutierrez Gammino, Graham Slater, et al.

    Introduction Heterogeneity in reported outcomes of infants with oesophageal atresia (OA) with or without tracheo-oesophageal fistula (TOF) prevents effective data pooling. Core outcome sets (COS) have been developed for many conditions to standardise outcome reporting, facilitate meta-analysis and improve the relevance of research for patients and families. Our aim is to develop an internationally-agreed, comprehensive COS for OA-TOF, relevant from birth through to transition and adulthood. Methods and analysis A long list of outcomes will be generated using (1) a systematic review of existing studies on OA-TOF and (2) qualitative research with children (patients), adults (patients) and families involving focus groups, semistructured interviews and self-reported outcome activity packs. A two-phase Delphi survey will then be completed by four key stakeholder groups: (1) patients (paediatric and adult); (2) families; (3) healthcare professionals; and (4) researchers. Phase I will include stakeholders individually rating the importance and relevance of each long-listed outcome using a 9-point Likert scale, with the option to suggest additional outcomes not already included. During phase II, stakeholders will review summarised results from phase I relative to their own initial score and then will be asked to rescore the outcome based on this information. Responses from phase II will be summarised using descriptive statistics and a predefined definition of consensus for inclusion or exclusion of outcomes. Following the Delphi process, stakeholder experts will be invited to review data at a consensus meeting and agree on a COS for OA-TOF. Ethics and dissemination Ethical approval was sought through the Health Research Authority via the Integrated Research Application System, registration no. 297026. However, approval was deemed not to be required, so study sponsorship and oversight were provided by Alder Hey Children’s NHS Foundation Trust. The study has been prospectively registered with the COMET Initiative. The study will be published in an open access forum.


  • Open Access

    Unsupervised home spirometry is not equivalent to supervised clinic spirometry in children and young people with cystic fibrosis: Results from the CLIMB‐CF study

    by Claire Edmondson, Nicole Westrupp, Christopher Short, Paul Seddon, Catherine Olden, Colin Wallis, Malcolm Brodlie, Francis Baxter, Jonathan McCormick, Susan MacFarlane, et al.

    Background: Handheld spirometry allows monitoring of lung function at home, of particular importance during the COVID‐19 pandemic. Pediatric studies are unclear on whether values are interchangeable with traditional, clinic‐based spirometry. We aimed to assess differences between contemporaneous, home (unsupervised) and clinic (supervised) spirometry and the variability of the former. The accuracy of the commercially available spirometer used in the study was also tested.Methods: Data from participants in the Clinical Monitoring and Biomarkers to stratify severity and predict outcomes in children with cystic fibrosisc (CLIMB‐CF) Study aged ≥ 6 years who had paired (±1 day) clinic and home forced expiratory volume in 1 s (FEV1) readings were analyzed. Variability during clinical stability over 6‐months was assessed. Four devices from Vitalograph were tested using 1 and 3 L calibration syringes.Results: Sixty‐seven participants (median [interquartile range] age 10.7 [7.6−13.9] years) provided home and clinic FEV1 data pairs. The mean (SD) FEV1% bias was 6.5% [±8.2%]) with wide limits of agreement (−9.6% to +22.7%); 76.2% of participants recorded lower results at home. Coefficient of variation of home FEV1% during stable periods was 9.9%. Data from the testing of the handheld device used in CLIMB‐CF showed a potential underread.Conclusion: In children and adolescents, home spirometry using hand‐held equipment cannot be used interchangeably with clinic spirometry. Home spirometry is moderately variable during clinical stability. New handheld devices underread, particularly at lower volumes of potential clinical significance for smaller patients; this suggests that supervision does not account fully for the discrepancy. Opportunities should be taken to obtain dual device measurements in clinic, so that trend data from home can be utilized more accurately.


  • Improvements in Glucose Regulation in Children and Young People with Cystic Fibrosis-Related Diabetes following Initiation of Elexacaftor/Tezacaftor/Ivacaftor

    by Julie Park, Anna Walsh, Sue Kerr, Clare Woodland, Suzanne Southward, Mark Deakin, Senthil Senniappan, Rebecca Thursfield

    Introduction: Cystic fibrosis transmembrane conductance regulator (CFTR) modulators are increasingly used in children and young people with cystic fibrosis (CF). Data in adults show there may be an impact on glycaemic control in those with CF-related diabetes (CFRD). Paediatric data are rare. Case Series/Presentation: Children aged >12 years with CFRD, who were eligible for elexacaftor/tezacaftor/ivacaftor (ELX/TEZ/IVA) were commenced on treatment. Glucose monitoring via the FreeStyle Libre system was commenced prior to, immediately after, and several months after commencing ELX/TEZ/IVA. Glycaemic control, shown by time in range (3–10 mmol/L), percentage of time spent hypoglycaemic (10 mmol/L) on Insulin doses were recorded. Following ELX/TEZ/IVA, four of seven children stopped insulin, two required substantially reduced doses of insulin, one showed no response. Glycaemic control remained similar on lower doses or no insulin. Hypoglycaemia was detected in those not requiring insulin. Conclusion: ELX/TEZ/IVA has a positive impact on glycaemic control and insulin requirements in children with CFRD. Close monitoring is required when commencing treatment. Children with CFRD need counselling regarding possible reductions in insulin requirement and re-education regarding symptoms, signs, and management of hypoglycaemia.


  • Rebuttal From Dr Thursfield et al

    by Rebecca M. Thursfield, Nadia Shafi, Jane C. Davies

  • The feasibility of home monitoring of young people with cystic fibrosis: Results from CLIMB-CF

    by C. Edmondson, N. Westrupp, P. Seddon, C. Olden, C. Wallis, C. Dawson, M. Brodlie, F. Baxter, J. McCormick, S. MacFarlane, et al.


  • Bronchiolitis obliterans - a review of this rare paediatric respiratory disorder

    by Jennifer Burrows, Rebecca Thursfield

    Background: Bronchiolitis obliterans (BO) is a rare form of chronic obstructive lung disease that follows and insult to the lower respiratory tract, often a viral infection and most commonly adenovirus. There are surprisingly little data on the clinical course and outcome, and physiological state of this group. Aims: The aim of this review was to establish the number of patients with BO at Alder hey Children’s Hospital, the cause and clinical course of these patients. Methods: A letter search from 2010 was carried out and diagnosis confirmed by reviewing the electronic patient records (EPR). EPR were then used to collate clinical data including presenting symptoms, microbiology and respiratory physiological investigation. Results: 58 patients were identified with a mean age at presentation to tertiary respiratory services 44 months, and mean age at diagnosis was 51 months. All patients had diagnosis confirmed with clinical history and compatible CT chest findings; one child underwent lung biopsy. Adenovirus was the most common organism to have been identified prior to diagnosis with 14% of patients isolating this. Respiratory function was significantly reduced with a mean FEV1 of 63.7% and mean FVC 78.6%. 2 patients had undergone further respiratory physiology testing; one with an overnight TOSCA (CO2/O2) study and the other a TOSCA study and hypoxic challenge testing. There was no consensus on management with 74% patients receiving inhaled steroids, 71% oral antibiotics and 15% intravenous antibiotics. Conclusion: This case series demonstrates that this group have severely limited respiratory function and would benefit from further research to establish physiological state and guidelines for optimal management.